Goldman Sachs recently reaffirmed its "Buy" rating on Eli Lilly (LLY.US) and increased its price target on the stock from $1,145 to $1,260. The firm stated that Eli Lilly's 2026 performance guidance indicates approximately 25% year-over-year revenue growth, reflecting sustained market confidence in the obesity drug segment despite gradually increasing pricing pressures. Goldman Sachs noted that market attention is likely to shift to the oral obesity medication orforglipron, which Eli Lilly plans to launch in the second quarter of 2026. Management indicated that the product's substitution effect on existing injectable therapies should be limited, and early signs support further expansion of the overall GLP-1 market. Eli Lilly's recently reported financial results showed fourth-quarter 2025 revenue climbed to $19.3 billion, surpassing market expectations of $17.96 billion. Earnings per share were $7.54, beating the anticipated $6.67. During the quarter, Zepbound sales reached $4.3 billion, exceeding expectations of $3.8 billion, while Mounjaro sales totaled $7.4 billion, also above the projected $6.7 billion. Concurrently, Eli Lilly provided an optimistic growth outlook for 2026, driven by robust demand for obesity treatments, which appears largely unaffected by pricing pressures. The company expects 2026 revenue to reach between $80 billion and $83 billion—significantly higher than the market consensus of $77.62 billion—implying growth of approximately 25%. This guidance underscores a competitive landscape increasingly shaped by consumer demand rather than insurance coverage. Eli Lilly also forecast 2026 earnings per share in the range of $33.50 to $35.00, with even the lower end of the range exceeding the market expectation of $33.23. Furthermore, according to remarks by Ken Custer, head of Eli Lilly's cardiometabolic health business, on the earnings call, the company anticipates launching orforglipron in the United States in the second quarter, with most international markets following in 2027.